|
Patent landscape, scope, and claims: |
US Patent 5,795,564: Scope, Claim-by-Claim Coverage, and US Landscape for (R,R)-Formoterol Low-(S,S) Bronchodilator Use
What does US 5,795,564 claim in plain scope terms?
US 5,795,564 is directed to methods and pharmaceutical compositions using an enantiomerically enriched (R,R)-formoterol that is defined by purity (≥99% (R,R) and <1% (S,S)), with two core performance objectives:
- Elicit bronchodilation while avoiding “concomitant liability of hypersensitivity.”
- Achieve longer or substantially longer bronchodilator duration than “comparable” racemic formoterol (claims 14-15).
The document therefore creates a US enforceable perimeter around:
- Material definition: enantiomeric composition and purity threshold.
- Biological/performance framing: “sufficient to alleviate bronchospasms but insufficient to cause hypersensitivity.”
- Dosing and routes: injection, infusion, inhalation, transdermal, oral; with numerical dose ranges for inhaled and oral forms.
- Product form factors: tablets, capsules, transdermal patches, aerosols.
Claim 1: The core method, tied to both purity and a hypersensitivity avoidance limitation
Claim 1 defines the fundamental method element:
- Administer to a human needing bronchodilation:
- (R,R)-formoterol or a pharmaceutically acceptable salt
- Amount is:
- sufficient to alleviate bronchospasms
- insufficient to cause hypersensitivity
- The administered (R,R)-formoterol contains:
- ≥99% by weight (R,R)-formoterol
- <1% by weight (S,S)-formoterol
Scope implications
- The claim is not limited to a specific route, device, or dosage form. Route limitations enter through dependent claims.
- The “hypersensitivity avoidance” phrase functions as a functional limitation tied to amount and outcome, not a specific biomarker or formulation parameter.
- Enantiopurity is a hard chemical boundary: if a competitor’s (R,R)-formoterol contains ≥1% (S,S), claim 1’s material definition is not met on its face.
Claims 2-7: Route and dose parameters, with a sub-range for inhaled and oral administration
Claim 2
Adds route options for the method of claim 1:
- subcutaneous injection
- intravenous infusion
- inhalation
- transdermal delivery
- oral administration
Claim 3 (inhalation dose window)
For inhalation:
- about 1 μg to about 100 μg per day
Claim 4 (oral dose window)
For oral administration:
- about 0.1 mg to about 1 mg per day
Claim 5
Adds formulation carrier:
- (R,R)-formoterol or salt administered with a pharmaceutically acceptable carrier
Claim 6
Specifies salt/form:
- (R,R)-formoterol fumarate dihydrate
Claim 7
Defines dosing schedule:
- “divided doses from two to four times a day” (dependent on claim 2)
Scope implications
- The inhalation and oral numerical ranges create dose-band infringement risk for enantiopure products used within those windows.
- Claims 2-7 make clear the claim set covers both drug substance administration and end-user dosing regimens, provided the drug substance meets the <1% (S,S) constraint.
- Claim 6 introduces an additional axis: use of the fumarate dihydrate form.
Claims 8-13: Product claims for bronchodilator compositions with the same purity restriction
Claim 8 (composition core)
Defines a bronchodilator composition comprising:
- pharmaceutically acceptable carrier
- an amount of (R,R)-formoterol or salt sufficient to alleviate bronchospasms but insufficient to cause hypersensitivity
- drug substance purity:
It also covers composition “in the form of”:
- tablet
- capsule
- transdermal patch
- aerosol
Claim 9 (inhalation composition dose)
For inhalation-adapted form:
- (R,R)-formoterol amount about 6 μg to about 25 μg (interpretable as per unit dose/device context; the claim does not explicitly say per day)
Claim 10
Specifies:
- (R,R)-formoterol fumarate dihydrate
Claim 11
For oral-adapted composition.
Claim 12 (oral dosage form amount)
- amount of formoterol in an oral dosage form:
Claim 13
For transdermal-adapted composition.
Scope implications
- Composition claims create a “manufacturing and supply” foothold: an infringing product does not require a specific prescriber behavior if the product, as formulated and dosed, meets claim parameters.
- Claim 9 can be strategically important in enforcement: it gives a narrower inhalation amount band than claim 3.
- The purity boundary remains common across all composition claims.
Claims 14-15: Performance-based duration claims versus racemic formoterol
Claim 14 (more than twice duration)
Method claim that adds a specific comparative pharmacodynamic outcome:
- Administer to a human needing bronchodilation:
- Amount sufficient to alleviate bronchospasms
- Produces bronchodilator effect:
- more than twice the duration of the effect of a “comparable dose” of racemic formoterol
- Purity:
Claim 15 (longer duration)
Similar structure but less stringent:
- Produces bronchodilator effect:
- longer duration than comparable dose of racemic formoterol
- Purity:
Scope implications
- These claims create a litigation-critical performance evidentiary path: infringement hinges on what “duration” means and how it is measured in the accused use.
- If a competitor argues the measured bronchodilator duration is not “more than twice” (claim 14) or is not “longer” (claim 15), the claim may narrow in practice even if chemical purity matches.
- The claims still require the same chemical purity threshold, so the material definition remains the first gate.
Claim coverage map: what you can and cannot design around easily
| Design variable |
Where it matters in 5,795,564 |
Infringement risk if you move away |
| Enantiomeric purity (≥99% (R,R), <1% (S,S)) |
Claims 1, 8, 14, 15 (and through dependency) |
High design-around leverage: using (R,R) with ≥1% (S,S) avoids literal compliance with the stated purity requirement. |
| “Hypersensitivity” liability avoidance |
Claims 1 and 8 (and composition analog) |
Medium leverage: if you change dosing to cause hypersensitivity, you may fall outside “insufficient to cause hypersensitivity,” but that is not a credible safety strategy. Litigation could also interpret outcomes and labeling. |
| Route |
Claim 2; composition format claims 8-13 |
Medium leverage: if you use a route not enumerated, you may avoid literal coverage, but note claim 1 covers “administering” without route specificity. |
| Inhaled dose band |
Claim 3 (1 to 100 μg/day) and claim 9 (6 to 25 μg) |
Medium leverage: if you stay outside the specified bands, you may reduce literal match, but claim 1’s functional “sufficient but insufficient to cause hypersensitivity” can still reach if the route/dose is otherwise within capability. |
| Oral dose band |
Claim 4 (0.1 to 1 mg/day) and claim 12 (0.1 to 1 mg per oral dosage form) |
Medium leverage depending on formulation unit sizing; claim 1 still has functional limitations without strict oral dosing. |
| Salt form |
Claims 6 and 10 |
Low-to-medium leverage: if you are not using fumarate dihydrate, dependent claims 6 and 10 avoid, but independent claim 1/8 remain. |
| Comparative duration vs racemic |
Claims 14 and 15 |
Evidentiary leverage: duration measurements can be argued; but if clinical data show longer duration for (R,R), risk rises. |
Enforceable “center of gravity” inside the patent
The most strategically enforceable elements are:
- Chemical definition: (R,R)-formoterol with ≥99% (R,R) and <1% (S,S) (present across independent claims 1, 8, 14, 15).
- Functional outcome framing tied to dose: “alleviate bronchospasms but insufficient to cause hypersensitivity” (claims 1, 8).
- Comparative duration: “more than twice” and “longer” versus racemic (claims 14, 15).
- Dose band constraints for inhalation and oral that can help enforcement against specific product regimens (claims 3, 4, 9, 12).
US patent landscape: how 5,795,564 positions against typical formoterol enantiomer and bronchodilator strategy
Because the claims are sharply focused on enantiomeric purity and use, the landscape around US 5,795,564 typically bifurcates into these competitive buckets:
-
Enantiomerically enriched (R,R)-formoterol products
- Risk concentrates where the supplier’s drug substance meets the <1% (S,S) threshold and the marketed dosing regimens fall within the inhaled/oral bands in dependent claims.
- If the product also seeks to claim superior duration versus racemic, it may implicate claims 14-15.
-
Racemic formoterol formulations (or lower enantiopurity “(R,R)-enriched” variants)
- If the active is racemic (50/50) or not confined to <1% (S,S), you avoid the material limitation but remain exposed to any separate racemate patents (not analyzed here).
-
Different enantiomer selections or different purity specifications
- The patent set is specifically tied to (R,R) and a very tight impurity ceiling for (S,S). Competitors using a slightly less pure (R,R) material may have an escape route on literal coverage.
-
Salt form and formulation technologies
- Dependent claims pick out fumarate dihydrate, but independent claims are not constrained to a salt form. That shifts many formulation design-around attempts into the “not enough” category unless they also change composition purity.
-
Alternative pharmacology claims
- If the commercial strategy shifts to different bronchodilators or different mechanisms, the overlap drops substantially. But within formoterol enantiomers, the competitive overlap stays anchored to purity and performance framing.
Practical infringement checkpoints for an R&D or BD team evaluating (R,R)-formoterol
- Drug substance analytics: confirm whether the supplied active meets ≥99% (R,R) and <1% (S,S) across specs and batches.
- Salt and dosage form: even if you avoid fumarate dihydrate, independent claims still matter.
- Route and dosing: check inhalation/oral daily ranges (claims 3-4) and per-dose inhalation/oral unit amounts (claim 9, 12).
- Clinical framing of duration: if marketing or clinical protocol data support “longer duration” relative to racemate, claims 14-15 become relevant.
- Labeling or study endpoint choices: duration claims invite disputes over “comparable dose” and how “duration” is defined and measured.
Key Takeaways
- US 5,795,564 is anchored on enantiomerically enriched (R,R)-formoterol with ≥99% (R,R) and <1% (S,S).
- The patent covers both methods (bronchospasm relief without hypersensitivity liability as framed) and compositions (tablet/capsule/patch/aerosol plus inhalation/oral/transdermal variants).
- Dependent claims narrow risk with inhalation and oral dose bands and a dosing frequency framework.
- Claims 14-15 add comparative duration superiority versus racemic formoterol, shifting additional enforcement into performance evidence.
FAQs
1) What is the critical chemical requirement in US 5,795,564?
The claims require (R,R)-formoterol containing at least 99% by weight (R,R) and less than 1% by weight (S,S).
2) Does the patent cover racemic formoterol?
The cited claims are explicitly tied to (R,R)-formoterol with the stated purity profile, and the comparison for claims 14-15 is versus racemic formoterol.
3) Are salt forms limited to fumarate dihydrate?
No. Fumarate dihydrate is in dependent claims (6 and 10), but independent method and composition claims require only (R,R)-formoterol or a pharmaceutically acceptable salt with the purity definition.
4) Where do the dose ranges appear?
In dependent claims: inhalation about 1 μg to about 100 μg/day (claim 3) and inhalation composition amount about 6 μg to about 25 μg (claim 9); oral daily about 0.1 to about 1 mg/day (claim 4) and oral dosage form amount 0.1 to 1 mg (claim 12).
5) What makes claims 14-15 harder to police than claims 1-8?
They require a comparative duration outcome (“more than twice” or “longer duration” versus racemic at “comparable dose”), which depends on test design and endpoint definitions.
References
[1] US Patent 5,795,564. “Method for eliciting a bronchodilator effect while avoiding concomitant liability of hypersensitivity,” issued by the United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
